

Althea announces the proposed appointment of Jakob Ripshtein as Aphria's representative Non-Executive Director and the stepping down of Gregg Battersby

- Aphria Inc. President, Jakob Ripshtein, is proposed to replace Mr Battersby as Non-Executive Director (pending ODC approval)
- The proposed appointment of Mr Ripshtein further enhances Althea's global partnership with leading Canadian cannabis producer, Aphria Inc.
- Gregg Battersby has stepped down from his Non- Executive Director role

Thursday 7 March 2019: **Australian medicinal cannabis company Althea Group Holdings Limited (ASX:AGH) ("Althea" or "the Company")** wishes to advise that Gregg Battersby has stepped down from his Non-Executive Director role and that Jakob Ripshtein, President of Aphria Inc (TSX: APHA and NYSE: APHA) ("**Aphria**"), is proposed to be appointed as a Non-Executive Director of the Company.

Althea and Aphria strengthening ties

Mr Battersby has been a director of Althea since its initial listing in September 2018 and the Board thanks Mr Battersby for his strong contribution to date.

The proposed appointment of Mr Ripshtein will continue Aphria's representation on the Althea board.

"Althea is excited at the proposal of Jakob joining its board and welcomes the level of experience which he will bring," Althea CEO, Josh Fegan said. "We value our partnership with Aphria and the nomination of Jakob to the Althea board, pending Office of Drug Control paperwork, will only enhance existing and future strategic initiatives."

As President of Aphria Inc. Mr Ripshtein oversees the company's strategic direction including partnerships, international expansion and global operations in 10 countries. Prior to his appointment as President, Mr. Ripshtein served as the Chief Commercial Officer, responsible for the company's sales, marketing and commercial strategy. Mr. Ripshtein previously worked at Diageo North America, the world's leading premium beverage organization holding various positions including VP Finance for Diageo Canada, President of Diageo Canada and CFO of Diageo North America.

"I look forward to increasing my involvement with Althea as they continue to build their Australian and international businesses," said President of Aphria, Mr Ripshtein. "Althea is one of the most active medical cannabis companies outside of Canada and I am very excited about their future."

For further information, please contact:

Althea

Josh Fegan

CEO & Managing Director
M: 1300 70 20 20
E: contact@althea.com.au

Media Enquiries

Julia Maguire

The Capital Network
M: +61 419 815 386
E: julia@thecapitalnetwork.com.au

Australian Investors

PAC Partners Securities

M: 03 8633 9834

E: enquiries@pacpartners.com.au

Media

Georgie Harrison

Keep Left

M: 03 9268 7800

E: georgia@keepleft.com.au

Althea Group Holdings Limited (ASX:AGH)

Althea is a patient-focussed medicinal cannabis company. Althea has become a leading supplier of medicinal cannabis products in Australia since it was founded in Melbourne in 2017 and was granted necessary licences and permits to import, cultivate, manufacture and supply medicinal cannabis for eligible patients in Australia in 2018. Through strategic supply and distribution partnerships, Althea has become a significant supplier of five Althea branded medicinal cannabis products in Australia.

Althea's focus on patient care underpins its business strategy and its innovative web-based platform and mobile application, known as Althea Concierge, is designed to educate and support patient access to medicinal cannabis in Australia and the United Kingdom. Althea has also engaged a team of medical science liaisons to assist medical practitioners to become prescribers, and pharmacists to become suppliers, of Althea products.

To learn more, please visit: www.althea.com.au